(R)-WAC-224, a new anticancer quinolone, combined with venetoclax and azacitidine overcomes venetoclax-resistant AML through MCL-1 downregulation

(R)-WAC-224, a new anticancer quinolone, combined with venetoclax and azacitidine overcomes venetoclax-resistant AML through MCL-1 downregulation

Abstract Hypomethylating agents combined with venetoclax (VEN), a BCL-2 inhibitor, represent a standard treatment strategy for patients with acute myeloid leukemia (AML). Although this combination is highly effective, acquired resistance commonly occurs. MCL-1, a BCL-2 family molecule, is frequently...

Full description

Saved in:
Bibliographic Details
Main Authors: Hiroshi Ureshino, Taichi Ueshima, Tomonori Yamaguchi, Miyuki Takashima, Yusuke Sanuki, Tatsuo Ichinohe
Format: Article
Language:English
Published: Nature Portfolio 2025-05-01
Series:Scientific Reports
Subjects:
Acute myeloid leukemia
(R)-WAC-224
Anticancer quinolone
Venetoclax
MCL-1
Online Access:https://doi.org/10.1038/s41598-025-98534-7
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41598-025-98534-7

Similar Items